Skip to main content
SpringerLink
Log in

Introduction: Metrics and Domains Measured in SLE

  • Chapter
  • First Online:
Outcome Measures and Metrics in Systemic Lupus Erythematosus

  • 555 Accesses

Abstract

Chapter 1 provides an overview of the five core domains for the appropriate assessment of patients with systemic lupus erythematosus (SLE) for research and clinical settings: disease activity, chronic damage resulting from lupus activity or its treatment, health-related quality of life (HRQoL), adverse events, and economic impact. Emerging concepts in SLE such as frailty are also introduced along with deep insights on selected existing concepts, in particular cognition, depression, and anxiety as well as fatigue. Having explored what needs to be measured in SLE, this chapter then outlines the decision-making process by which candidate instruments are identified and determined to be a match for the target construct (e.g., disease activity).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  1. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685–91. PubMed PMID: 10568907. Epub 1999/11/24

    Article  CAS  PubMed  Google Scholar 

  2. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–8. PubMed PMID: 19714602. Epub 2009/08/29

    Article  PubMed  Google Scholar 

  3. Waldheim E, Elkan AC, Bergman S, Frostegard J, van Vollenhoven R, Henriksson EW. Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus. Lupus. 2013;22(2):136–43. PubMed PMID: 23192324. Epub 2012/11/30

    Article  CAS  PubMed  Google Scholar 

  4. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955–9. PubMed PMID: 12966597. Epub 2003/09/11

    PubMed  Google Scholar 

  5. Touma Z, Gladman D, Urowitz M. Clinical measures, metrics and indices. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus and related syndromes. 8th ed: Elsevier Inc; 2013. p. 532–81.

    Google Scholar 

  6. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus. 2000;9(5):322–7. PubMed PMID: 10878722. Epub 2000/07/06

    Article  CAS  PubMed  Google Scholar 

  7. Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119–33. PubMed PMID: 17907227. Epub 2007/10/02

    Article  PubMed  Google Scholar 

  8. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–12. PubMed PMID: 31385462. PubMed Central PMCID: PMC6827566. Epub 2019/08/07

    Article  PubMed  PubMed Central  Google Scholar 

  9. Singh JA, Solomon DH, Dougados M, Felson D, Hawker G, Katz P, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348–52. PubMed PMID: 16739201. Epub 2006/06/02

    Article  PubMed  Google Scholar 

  10. Nuttall A, Isenberg DA. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. Best Pract Res Clin Rheumatol. 2013;27(3):309–18. PubMed PMID: 24238688. Epub 2013/11/19

    Article  PubMed  Google Scholar 

  11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40. PubMed PMID: 1599520. Epub 1992/06/01

    Article  CAS  PubMed  Google Scholar 

  12. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol. 2000;27(2):377–9. PubMed PMID: 10685800. Epub 2000/02/24

    CAS  PubMed  Google Scholar 

  13. Touma Z, Moghaddam B, Su J, Katz P. Cognitive function trajectories are associated with the depressive symptoms trajectories in systemic lupus erythematosus over time. Arthritis Care Res. 2020. PubMed PMID: 32526080. Epub ahead of print.

    Google Scholar 

  14. Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology. 2018;57(8):1370–6. PubMed PMID: 29688532.

    Article  CAS  PubMed  Google Scholar 

  15. Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol. 2013;40(5):733. PubMed PMID: 23637378. Epub 2013/05/03

    Article  PubMed  Google Scholar 

  16. Pike MC, Kelley L. Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep. 2012;14(4):324–33. PubMed PMID: 22580894. PubMed Central PMCID: PMC3387490. Epub 2012/05/15

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91. PubMed PMID: 11838846. Epub 2002/02/13. eng

    PubMed  Google Scholar 

  18. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 2010;19(1):49–51. PubMed PMID: 19910390.

    Article  CAS  PubMed  Google Scholar 

  19. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67–70. PubMed PMID: 21233149. Epub 2011/01/15. eng

    Article  CAS  PubMed  Google Scholar 

  20. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19(10):1551–8. PubMed PMID: 1464867. eng.

    CAS  PubMed  Google Scholar 

  21. Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004;31(10):1934–40. PubMed PMID: 15468356. eng.

    PubMed  Google Scholar 

  22. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Eng J Med. 2005;353(24):2550–8. PubMed PMID: 16354891. eng.

    Article  CAS  Google Scholar 

  23. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2(SLEDAI-2K) Responder Index (SRI-50): a valid index for measuring improvement in disease activity. Arthritis &Rheumatism. 2010;62(Suppl 10):1878.

    Google Scholar 

  24. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011;38(2):275–84. PubMed PMID: 21123323. Epub 2010/12/03. eng

    Article  PubMed  Google Scholar 

  25. Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, et al. SLEDAI-2K responder index (SRI)-50:a reliable index for measuring improvement in disease activity. J Rheumatol. 2011;38(6):1171–2.

    Google Scholar 

  26. Touma Z, Gladman DD, Zandy M, Su J, Anderson N, Urowitz MB. Identifying a response for the systemic lupus erythematosus disease activity glucocorticoid index (SLEDAI-2KG). Arthritis Care Res. 2020. PubMed PMID: 32433815. Epub ahead of print.

    Google Scholar 

  27. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988;69(259):927–37. PubMed PMID: 3271336. eng.

    CAS  PubMed  Google Scholar 

  28. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447–58. PubMed PMID: 8210301. eng.

    CAS  PubMed  Google Scholar 

  29. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–6. PubMed PMID: 15814577. eng.

    Article  CAS  PubMed  Google Scholar 

  30. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32(9):1107–18. PubMed PMID: 2775320. eng.

    Article  CAS  PubMed  Google Scholar 

  31. Olesinska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 2018;56(1):45–54. PubMed PMID: 29686443. PubMed Central PMCID: PMC5911658. Epub 2018/04/25

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10(6):405–9. PubMed PMID: 11434575. eng.

    Article  CAS  PubMed  Google Scholar 

  33. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus. 2003;12(4):280–6. PubMed PMID: 12729051. eng.

    Article  CAS  PubMed  Google Scholar 

  34. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10(5):549–54. PubMed PMID: 1458711. eng.

    CAS  PubMed  Google Scholar 

  35. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10(5):527–39. PubMed PMID: 1458709. eng.

    CAS  PubMed  Google Scholar 

  36. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10(5):541–7. PubMed PMID: 1458710. eng.

    CAS  PubMed  Google Scholar 

  37. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19(1):53–9. PubMed PMID: 1556700. Epub 1992/01/01. eng

    CAS  PubMed  Google Scholar 

  38. Smolen JS. Clinical and serological features: incidence and diagnostic approach. In: Smolen JS, Zielinski CC, editors. Systemic lupus erythematosus: clinical and experimental aspects. Berlin/Heidelberg: Springer-Verlag; 1987. p. 170–96.

    Chapter  Google Scholar 

  39. Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K, et al. RIFLE: responder index for lupus erythematosus. Arthritis Rheum. 2000;43:S244.

    Google Scholar 

  40. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9. PubMed PMID: 8607884. Epub 1996/03/01. eng

    Article  CAS  PubMed  Google Scholar 

  41. Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliott J, et al. Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res. 2010;62(4):559–68. PubMed PMID: 20391512. eng.

    Article  Google Scholar 

  42. Pons-Estel BA, Sanchez-Guerrero J, Romero-Diaz J, Iglesias-Gamarra A, Bonfa E, Borba EF, et al. Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus. 2009;18(12):1033–52. PubMed PMID: 19762375. eng.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66. PubMed PMID: 8277801.

    Article  CAS  PubMed  Google Scholar 

  44. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972–9. PubMed PMID: 17665467.

    Article  PubMed  Google Scholar 

  45. Jolly M, Pickard AS, Wilke C, Mikolaitis RA, Teh LS, McElhone K, et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2010;69(1):29–33. PubMed PMID: 19126561. Epub 2009/01/08

    Article  CAS  PubMed  Google Scholar 

  46. Gonzalez-Rodriguez V, Peralta-Ramirez MI, Navarrete-Navarrete N, Callejas-Rubio JL, Santos Ruiz AM, Khamashta M. Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: the Lupus quality of life. Med Clin. 2010;134(1):13–6. PubMed PMID: 19647276. Adaptacion y validacion de la version espanola de una medida especifica de la calidad de vida en los pacientes con lupus eritematoso sistemico: el Lupus Quality of Life. spa.

    Article  Google Scholar 

  47. Grootscholten C, Ligtenberg G, Derksen RH, Schreurs KM, de Glas-Vos JW, Hagen EC, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12(6):635–44. PubMed PMID: 14516173. Epub 2003/10/01

    Article  CAS  PubMed  Google Scholar 

  48. Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology. 2005;44(10):1267–76. PubMed PMID: 15797980. Epub 2005/03/31

    Article  CAS  PubMed  Google Scholar 

  49. Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68(2):196–200. PubMed PMID: 18385276. Epub 2008/04/04

    Article  CAS  PubMed  Google Scholar 

  50. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51. PubMed PMID: 19714615. PubMed Central PMCID: PMC2748175. Epub 2009/08/29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):809–13. PubMed PMID: 9153540. Epub 1997/05/01

    Article  CAS  PubMed  Google Scholar 

  52. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700–6. PubMed PMID: 16887417. Epub 2006/08/05

    Article  PubMed  Google Scholar 

  53. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35(11):2152–8. PubMed PMID: 18793004. Epub 2008/09/17

    Article  PubMed  Google Scholar 

  54. Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76(12):2009–16. PubMed PMID: 28794077. Epub 2017/08/11

    Article  PubMed  Google Scholar 

  55. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus–a 5-yr prospective study. Rheumatology. 2004;43(8):1039–44. PubMed PMID: 15161983. Epub 2004/05/27

    Article  CAS  PubMed  Google Scholar 

  56. Keeling SO, Vandermeer B, Medina J, Chatterley T, Nevskaya T, Pope J, et al. Measuring disease activity and damage with validated metrics: a systematic review on mortality and damage in systemic lupus erythematosus. J Rheumatol. 2018;45(10):1448–61. PubMed PMID: 30111638. Epub 2018/08/17

    Article  PubMed  Google Scholar 

  57. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, et al. Canadian rheumatology association recommendations for the assessment and monitoring of systemic lupus erythematosus. J Rheumatol. 2018;45(10):1426–39. PubMed PMID: 30173152.

    Article  PubMed  Google Scholar 

  58. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol. 1992;19(11):1820–1. PubMed PMID: 1362779. Epub 1992/11/01

    CAS  PubMed  Google Scholar 

  59. Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibanez D, Fortin PR, et al. Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus. Clin Exp Rheumatol. 2010;28(4):525–31. PubMed PMID: 20659409.

    CAS  PubMed  Google Scholar 

  60. Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352–61. PubMed PMID: 23786872. Epub 2013/06/22

    Article  PubMed  Google Scholar 

  61. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93–6. PubMed PMID: 11237132. Epub 2001/03/10

    Article  CAS  PubMed  Google Scholar 

  62. Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, et al. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2010;62(3):335–44. PubMed PMID: 20391479. PubMed Central PMCID: PMC2946212. Epub 2010/04/15

    Article  Google Scholar 

  63. Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res. 2011;63(Suppl 11):S112–7. PubMed PMID: 22588739. Epub 2012/05/25

    Article  Google Scholar 

  64. Brunner HI, Silverman ED, Bombardier C, Feldman BM. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2003;49(3):335–41. PubMed PMID: 12794788. Epub 2003/06/10

    Article  PubMed  Google Scholar 

  65. Sato JO, Corrente JE, Saad-Magalhaes C. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus. Lupus. 2016;25(13):1479–84. PubMed PMID: 27230556. Epub 2016/05/28

    Article  CAS  PubMed  Google Scholar 

  66. Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77(6):855–60. PubMed PMID: 29463519. PubMed Central PMCID: PMC6037310. Epub 2018/02/22

    PubMed  Google Scholar 

  67. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–85. PubMed PMID: 27457513. PubMed Central PMCID: PMC5446003. Epub 2016/07/28

    Article  CAS  PubMed  Google Scholar 

  68. Buyon JP, Kalunian KC, Ramsey-Goldman R, Petri MA, Lockshin MD, Ruiz-Irastorza G, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999;8(8):677–84. PubMed PMID: 10568906. Epub 1999/11/24

    Article  CAS  PubMed  Google Scholar 

  69. Andreoli L, Gerardi MC, Fernandes M, Bortoluzzi A, Bellando-Randone S, Brucato A, et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev. 2019;18(2):164–76. PubMed PMID: 30572134. Epub 2018/12/21

    Article  PubMed  Google Scholar 

  70. Yazdany J, Yelin E. Health-related quality of life and employment among persons with systemic lupus erythematosus. Rheum Dis Clin N Am. 2010;36(1):15–32. vii. PubMed PMID: 20202589. PubMed Central PMCID: PMC2833285. Epub 2010/03/06.

    Article  Google Scholar 

  71. Panopalis P, Clarke AE. Quality of life in systemic lupus erythematosus. Clin Dev Immunol. 2006;13(2–4):321–4. PubMed PMID: 17162373. PubMed Central PMCID: PMC2270782. Epub 2006/12/13

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kwan A, Strand V, Touma Z. The role of patient-reported outcomes in systemic lupus erythematosus. Curr Treat Options Rheum. 2017;3:308–21.

    Article  Google Scholar 

  73. Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363–75. PubMed PMID: 24238693. Epub 2013/11/19

    Article  CAS  PubMed  Google Scholar 

  74. Bultink IE, Turkstra F, Dijkmans BA, Voskuyl AE. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol. 2008;35(6):1053–7. PubMed PMID: 18381792. Epub 2008/04/03

    PubMed  Google Scholar 

  75. Strand V, Simon LS, Meara AS, Touma Z. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med. 2020;7(1):e000373. PubMed PMID: 32591423. Epub 2020/06/28

    Article  PubMed  PubMed Central  Google Scholar 

  76. Kwan A, Katz P, Touma Z. The assessment of anxiety and depression and its associated factors in SLE. Curr Rheumatol Rev. 2019;15(2):90–8. PubMed PMID: 30255761. Epub 2018/09/27

    Article  PubMed  Google Scholar 

  77. Yee CS, McElhone K, Teh LS, Gordon C. Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects. Best Pract Res Clin Rheumatol. 2009;23(4):457–67. PubMed PMID: 19591777. Epub 2009/07/14

    Google Scholar 

  78. Jolly M, Garris CP, Mikolaitis RA, Jhingran PM, Dennis G, Wallace DJ, et al. Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus. Arthritis Care Res. 2014;66(10):1542–50. PubMed PMID: 24757021. Epub 2014/04/24

    Article  Google Scholar 

  79. Azizoddin DR, Weinberg S, Gandhi N, Arora S, Block JA, Sequeira W, et al. Validation of the LupusPRO version 1.8: an update to a disease-specific patient-reported outcome tool for systemic lupus erythematosus. Lupus. 2018;27(5):728–37. PubMed PMID: 29087259. Epub 2017/11/01

    Article  CAS  PubMed  Google Scholar 

  80. Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register; December 3, 2009. p. 65132–3.

    Google Scholar 

  81. Katz P, Pedro S, Alemao E, Yazdany J, Dall’Era M, Trupin L, et al. Estimates of responsiveness, minimally important differences, and patient acceptable symptom state in five patient-reported outcomes measurement information system short forms in systemic lupus erythematosus. ACR Open Rheumatol. 2020;2(1):53–60. PubMed PMID: 31943975. PubMed Central PMCID: PMC6957915. Epub 2020/01/17

    Article  PubMed  Google Scholar 

  82. Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, et al. Challenges and progress in adverse event ascertainment and reporting in clinical trials. J Rheumatol. 2005;32(10):2030–2. PubMed PMID: 16206364. Epub 2005/10/06

    PubMed  Google Scholar 

  83. Tian J, Luo Y, Wu H, Long H, Zhao M, Lu Q. Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. Lupus Sci Med. 2018;5(1):e000253. PubMed PMID: 29644081. PubMed Central PMCID: PMC5890859. Epub 2018/04/13

    PubMed  PubMed Central  Google Scholar 

  84. Gazarian M, Tugwell P, Boers M, Bombardier C, Brooks P, Day R, et al. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology. J Rheumatol. 1999;26(1):207–9. PubMed PMID: 9918265. Epub 1999/01/26

    CAS  PubMed  Google Scholar 

  85. Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, et al. Developing an OMERACT core outcome set for assessing safety components in rheumatology trials: the OMERACT safety working group. J Rheumatol. 2017;44(12):1916–9. PubMed PMID: 27744393. Epub 2016/10/17

    Article  PubMed  Google Scholar 

  86. Lau CS, Yin G, Mok MY. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus. 2006;15(11):715–9. PubMed PMID: 17153840. Epub 2006/12/13

    Article  CAS  PubMed  Google Scholar 

  87. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol. 2003;30(4):891–6. PubMed PMID: 12672224. Epub 2003/04/03

    PubMed  Google Scholar 

  88. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009;5(7):400–4. PubMed PMID: 19506585. Epub 2009/06/10

    Article  PubMed  Google Scholar 

  89. Doria A, Briani C. Lupus: improving long-term prognosis. Lupus. 2008;17(3):166–70. PubMed PMID: 18372355. Epub 2008/03/29

    Article  CAS  PubMed  Google Scholar 

  90. Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, et al. Economic evaluation of lupus nephritis in the systemic lupus international collaborating clinics inception cohort using a multistate model approach. Arthritis Care Res. 2018;70(9):1294–302. PubMed PMID: 29193883. PubMed Central PMCID: PMC6155450. Epub 2017/12/02

    Article  Google Scholar 

  91. Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus. 1999;8(8):645–54. PubMed PMID: 10568902. Epub 1999/11/24

    Article  CAS  PubMed  Google Scholar 

  92. Katz P, Nelson WW, Daly RP, Topf L, Connolly-Strong E, Reed ML. Patient-reported lupus flare symptoms are associated with worsened patient outcomes and increased economic burden. J Manag Care Spec Pharm. 2020;26(3):275–83. PubMed PMID: 32105178. Epub 2020/02/28

    PubMed  Google Scholar 

  93. Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, et al. Economic evaluation of damage accrual in an international SLE inception cohort using a multistate model approach. Arthritis Care Res. 2020;72(12):1800–8. PubMed PMID: 31609532.

    Google Scholar 

  94. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.

    Article  Google Scholar 

  95. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10(6):338–47. PubMed PMID: 24514913.

    Article  CAS  PubMed  Google Scholar 

  96. Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(2):240–55. PubMed PMID: 29571540. Epub 2018/03/25

    Article  PubMed  Google Scholar 

  97. Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol. 1994;21(10):1825–31. PubMed PMID: 7837145. Epub 1994/10/01. eng

    CAS  PubMed  Google Scholar 

  98. Glanz BI, Slonim D, Urowitz MB, Gladman DD, Gough J, MacKinnon A. Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry Neuropsychol Behav Neurol. 1997;10(4):232–8. PubMed PMID: 9359119. Epub 1997/11/14

    CAS  PubMed  Google Scholar 

  99. Tayer-Shifman OE, Green R, Beaton D, Ruttan L, Wither JE, Tartaglia MC, et al. Validity evidence supports the use of automated neuropsychological assessment metrics as a screening tool for cognitive impairment in lupus. Arthritis Care Res. 2019;72(12):1809–19. PubMed PMID: 31628718. Epub 2019/10/20. eng

    Article  Google Scholar 

  100. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  101. Hanly JG, Urowitz MB, Su L. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008;59(5):721–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol. 2015;67(7):1837–47. PubMed PMID: 25778456. PubMed Central PMCID: PMC4485527. Epub 2015/03/18

    Article  PubMed  PubMed Central  Google Scholar 

  103. Eldeiry D, Zandy M, Tayer-Shifman OE, Kwan A, Marzouk S, Su J, et al. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus. Rheumatology. 2020;59(11):3211–20. PubMed PMID: 32221602. Epub 2020/03/30

    Article  PubMed  Google Scholar 

  104. Moustafa AT, Moazzami M, Engel L, Bangert E, Hassanein M, Marzouk S, et al. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(1):84–94. PubMed PMID: 31303437. Epub 2019/07/16

    Article  PubMed  Google Scholar 

  105. Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum. 2010;62(5):1478–86. PubMed PMID: 20155829.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Zirkee EH, Bollen E, Buchem MA. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31–8.

    Article  Google Scholar 

  107. Shen J, Barbera J, Shapiro CM. Distinguishing sleepiness and fatigue: focus on definition and measurement. Sleep Med Rev. 2006;10(1):63–76. PubMed PMID: 16376590. Epub 2005/12/27

    Article  PubMed  Google Scholar 

  108. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol. 2002;29(3):482–6. PubMed PMID: 11908560. Epub 2002/03/23

    PubMed  Google Scholar 

  109. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol. 2005;32(9):1699–705. PubMed PMID: 16142863. Epub 2005/09/06

    PubMed  Google Scholar 

  110. Di Franco M, Guzzo MP, Spinelli FR, Atzeni F, Sarzi-Puttini P, Conti F, et al. Pain and systemic lupus erythematosus. Reumatismo. 2014;66(1):33–8. PubMed PMID: 24938194. Epub 2014/06/19

    Article  PubMed  Google Scholar 

  111. Petri M, Kawata AK, Fernandes AW, Gajria K, Greth W, Hareendran A, et al. Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus. J Rheumatol. 2013;40(11):1865–74. PubMed PMID: 24085548. Epub 2013/10/03

    Article  PubMed  Google Scholar 

  112. Elefante E, Tani C, Stagnaro C, Ferro F, Parma A, Carli L, et al. Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus. RMD Open. 2020;6(1):e001133. PubMed PMID: 32075876. PubMed Central PMCID: PMC7046978. Epub 2020/02/23

    Article  PubMed  PubMed Central  Google Scholar 

  113. Azizoddin DR, Gandhi N, Weinberg S, Sengupta M, Nicassio PM, Jolly M. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus. 2019;28(2):163–73. PubMed PMID: 30580659. Epub 2018/12/26

    Article  CAS  PubMed  Google Scholar 

  114. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum. 2007;57(8):1348–57.

    Article  Google Scholar 

  115. Barbacki A, Petri M, Avina-Zubieta A, Alarcon GS, Bernatsky S. Fatigue measurements in systemic lupus erythematosus. J Rheumatol. 2019;46(11):1470–7. PubMed PMID: 30709953. Epub 2019/02/03

    Article  CAS  PubMed  Google Scholar 

  116. Moses N, Wiggers J, Nicholas C. Persistence of unmet need for care among people with systemic lupus erythematosus: a longitudinal study. Qual Life Res. 2008;17(6):867–76. PubMed PMID: 18553154. Epub 2008/06/17

    Article  PubMed  Google Scholar 

  117. Danoff-Burg S, Friedberg F. Unmet needs of patients with systemic lupus erythematosus. Behav Med. 2009;35(1):5–13. PubMed PMID: 19297299. PubMed Central PMCID: PMC2687813. Epub 2009/03/20

    Article  PubMed  PubMed Central  Google Scholar 

  118. Rockwood K, Fox RA, Stolee P, Robertson D, Beattie BL. Frailty in elderly people: an evolving concept. CMAJ. 1994;150(4):489–95. PubMed PMID: 8313261. PubMed Central PMCID: PMC1486322. Epub 1994/02/15

    CAS  PubMed  PubMed Central  Google Scholar 

  119. Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, et al. Aging, frailty and age-related diseases. Biogerontology. 2010;11(5):547–63. PubMed PMID: 20559726. Epub 2010/06/19

    Article  CAS  PubMed  Google Scholar 

  120. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–22. PubMed PMID: 30065258. PubMed Central PMCID: PMC6146930. Epub 2018/08/02

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Katz PP, Andrews J, Yazdany J, Schmajuk G, Trupin L, Yelin E. Is frailty a relevant concept in SLE? Lupus Sci Med. 2017;4(1):e000186. PubMed PMID: 28243456. PubMed Central PMCID: PMC5294024. Epub 2017/03/01

    Article  PubMed  PubMed Central  Google Scholar 

  122. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, et al. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. J Rheumatol. 2020;47(1):72–81. PubMed PMID: 30988130. PubMed Central PMCID: PMC6800806. Epub 2019/04/17

    Article  PubMed  Google Scholar 

  123. Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, et al. Instrument selection using the OMERACT filter 2.1: the OMERACT methodology. J Rheumatol. 2019;46(8):1028–35. PubMed PMID: 30709952. Epub 2019/02/03

    Article  PubMed  Google Scholar 

  124. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol. 1995;48(1):9–18. PubMed PMID: 7853053.

    Article  CAS  PubMed  Google Scholar 

  125. Castellanos FX, Margulies DS, Kelly C, Uddin LQ, Ghaffari M, Kirsch A, et al. Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(3):332–7. PubMed PMID: 17888409. PubMed Central PMCID: 2745053.

    Article  PubMed  Google Scholar 

  126. EULAR. EULAR recommendations: EULAR/ACR collaborative projects. Accessed 7 Aug 2020.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of the West Indies-Mona, Kingston 7, Jamaica

    Taneisha K. McGhie

  2. Institute for Work & Health, Toronto, ON, Canada

    Dorcas E. Beaton

  3. Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Diane Lacaille

  4. Schroeder Arthritis Institute, University Health Network, University of Toronto, Toronto, ON, Canada

    Joan E. Wither

  5. Division of Rheumatology, Sinai Health System/University Health Network, University of Toronto, Toronto, ON, Canada

    Jorge Sanchez-Guerrero

  6. Centre for Prognosis in Rheumatic Disease, Toronto Lupus Clinic, Division of Rheumatology, Department of Medicine, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Zahi Touma

Authors
  1. Taneisha K. McGhie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorcas E. Beaton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane Lacaille
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joan E. Wither
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jorge Sanchez-Guerrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zahi Touma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahi Touma .

Editor information

Editors and Affiliations

  1. Medicine, University of Toronto, Toronto, ON, Canada

    Zahi Touma

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McGhie, T.K., Beaton, D.E., Lacaille, D., Wither, J.E., Sanchez-Guerrero, J., Touma, Z. (2021). Introduction: Metrics and Domains Measured in SLE. In: Touma, Z. (eds) Outcome Measures and Metrics in Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-030-73303-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73303-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73302-5

  • Online ISBN: 978-3-030-73303-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation